Risk-averse investors threaten drug development
Monday 16 June 2008
New drug development by the biotechnology industry is threatened by increasingly risk-averse investors and intensifying competition from generic rivals, a survey shows.
A major cause of investor wariness is the growing caution of the US Food and Drug Administration in granting marketing approval for new drugs. This in turn cuts into the time that the treatment is protected by patent, the survey, by the law firm Marks & Clerk, found.
Of the biotech and pharmaceutical executives surveyed, 90 per cent said that secondary and further funding would become harder to secure. Investors will instead focus on less-risky, later-stage drug development in an attempt to limit their risk exposure, prompting biotech companies to switch to these activities, the survey found.
Where capital is available, the terms are set to become more onerous for companies seeking investment.
The survey found that 80 per cent of respondents expected key investors to seek a bigger equity stake or to look to secure their capital against drug-makers' intellectual property assets.
Some 78 per cent of respondents stated that the climate for biotech innovation had got worse over the past year, with 89 per cent predicting that small or early-stage companies would either fail or be bought out at unattractive levels.
Competition from generic drugs manufacturers is also putting the industry under pressure, with three-quarters of respondents reporting that patents are harder to protect against generic producers than in the past.
Dr Gareth Williams, partner at Marks & Clerk and co-author of the report, said: "Biotechnology represents the future of modern medicine, where yesterday's innovators now struggle with dwindling pipelines, generic competition and a chequered R&D record.
"Whilst the long-term view has not changed, we are seeing a short to mid-term funding gap in the current climate, which poses a genuine risk to essential, early-stage research and development."
The survey is based on the views of 484 responses from senior executives in the industry, mainly in the US and the UK.
Britain First criticised for using actress's memory to draw attention to their 'hate-filled home page'
- 1 This 'woman calls police to order pizza' story isn't going where you're expecting
- 2 Axe wielding man shot dead after attacking four New York policemen on busy street
- 3 Watch what happened when food critics were unknowingly served McDonald's
- 4 Jimmy Carr's Oscar Pistorius joke goes a bit too far at the Q Awards
- 5 Ottawa shootings: Bruce MacKinnon's cartoon is the perfect tribute to soldier Nathan Cirillo
Renee Zellweger on plastic surgery rumours: 'I'm living a more fulfilling life and I'm thrilled that perhaps it shows'
FCKH8: YouTube reinstates provocative anti-sexism video showing young girls swearing
Axe wielding man shot dead after attacking four New York policemen on busy street
This 'woman calls police to order pizza' story isn't going where you're expecting
Jimmy Carr's Oscar Pistorius joke goes a bit too far at the Q Awards
Of course, teenage girls need role models – but not like beauty vlogger Zoella
Cameron is warned 'no possibility' of UK reducing immigration and that bid to bring in quota on migrant workers would be illegal
Support for EU membership 'at highest level since 1991' with most Brits wanting to stay 'in'
Thousands with degenerative conditions classified as 'fit to work in future' – despite no possibility of improvement
Residents should throw a street party and mix with immigrant neighbours, councils told
Attacks on 'Ukip Calypso' show how skewed people’s priorities are
iJobs Money & Business
£60000 per annum: Ashdown Group: Compensation and Benefits Manager - Compensat...
£30000 - £35000 Per Annum plus excellent benefits: Clearwater People Solutions...
£24000 - £28000 per annum + bonus & benefits: Ashdown Group: IT Business Syste...
£50000 - £90000 per annum + benefits: Ampersand Consulting LLP: Markit EDM (CA...